Ftse Mib
34.492,41
0,13%
DAX
18.497,94
-0,09%
S&P 500
5.277,51
0,80%
NASDAQ
16.735,02
-0,01%
Bitcoin
67.765,42
0,42%
Registration Strip Icon for alerts Registrati per avvisi in tempo reale, portafoglio personalizzato e movimenti di mercato.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ ALX Oncology Holdings Inc (ALXO) ALX Oncology Holdings Inc (ALXO) Notizie

ALX Oncology Holdings Inc

ALXO
10,63
-0,02 (-0,19%)
01 Giu 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
29/5/202415:00GLOBEALX Oncology Announces Participation in the Jefferies Global..
15/5/202422:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202422:06EDGAR2Form 144 - Report of proposed sale of securities
09/5/202422:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/5/202422:00GLOBEALX Oncology Reports First Quarter 2024 Financial Results..
08/5/202423:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/5/202415:00GLOBEALX Oncology Appoints Allison Dillon as Chief Business..
06/5/202422:02EDGAR2Form 144 - Report of proposed sale of securities
30/4/202415:00GLOBEALX Oncology Announces Initiation of Phase 2..
24/4/202416:00GLOBEALX Oncology Announces Two Evorpacept Abstracts Accepted for..
09/4/202423:30GLOBEALX Oncology Reports Encouraging Clinical Data of Evorpacept..
07/3/202422:05EDGAR2Form 8-K - Current report
07/3/202422:03GLOBEALX Oncology Reports Fourth Quarter and Full Year 2023..
05/3/202422:30GLOBEALX Oncology Announces Two Evorpacept Clinical Abstracts..
17/2/202400:24EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202400:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
17/2/202400:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/1/202422:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:28EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:25EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202422:17EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03/1/202414:00GLOBEALX Oncology to Present at the 42nd Annual J.P. Morgan..
26/12/202322:01EDGAR2Form 8-K - Current report
13/11/202322:05GLOBEALX Oncology Reports Third Quarter 2023 Financial Results..
13/11/202322:03EDGAR2Form 8-K - Current report
01/11/202321:05GLOBEALX Oncology Announces November Investor Conference..
10/10/202322:05GLOBEALX Oncology Announces Closing of Public Offering, Including..
06/10/202312:06EDGAR2Form 8-K - Current report
06/10/202312:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
05/10/202314:00GLOBEALX Oncology Announces Pricing of Public Offering
04/10/202323:21EDGAR2Form 8-K - Current report
04/10/202323:21EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
04/10/202322:10GLOBEALX Oncology Announces Proposed Public Offering
04/10/202314:00EDGAR2Form 8-K - Current report
03/10/202316:03IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Recommendations
03/10/202312:00GLOBEALX Oncology Reports Positive Interim Phase 2 ASPEN-06..
02/10/202322:05GLOBEALX Oncology to Host Investor Call and Webcast on October 3,..
20/9/202314:45IHNWPathways to Progress: How Orphan Drug Designation Sparks..
11/9/202306:15EDGAR2Form EFFECT - Notice of Effectiveness
08/9/202322:25EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
06/9/202322:05EDGAR2Form 8-K - Current report
06/9/202314:00GLOBEALX Oncology Realigns Executive Leadership Team
01/9/202322:11EDGAR2Form S-3 - Registration statement under Securities Act of..
31/8/202313:00GLOBEALX Oncology Announces September Investor Conference..
25/8/202322:44EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
10/8/202322:10EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
10/8/202322:05EDGAR2Form 8-K - Current report
10/8/202322:01GLOBEALX Oncology Reports Second Quarter 2023 Financial Results..
27/7/202322:27EDGAR2Form 4 - Statement of changes in beneficial ownership of..
27/7/202322:19EDGAR2Form 4 - Statement of changes in beneficial ownership of..
Apertura: 10,61 Min: 10,44 Max: 11,08
Chiusura: 10,65

La tua Cronologia

NASDAQ
ALXO
ALX Oncology
BITMOT
880611
Esm Tf 0% Mz25 Eur
KOSPI
317400
Xi S and D
LSE
RED
Redt Energy
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network